PREVIOUS PAPERS

Ader F. et al.
An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Clin. Microbiol. Infect. 2021 May 25
Royer G. et al.
Developing Tools to Evaluate Non-linear Mixed Effect Models: 20 Years on the npde Adventure.
CAAPS J. 2021 May 19

Royer G. et al.
O-antigen targeted vaccines against E. coli may be useful in reducing morbidity, mortality and antimicrobial resistance.
Clin. Infect. Dis. 2021 May 17

Manchon P. et al.
Evaluation by simulation of clinical trial designs for evaluation of treatment during a viral haemorrhagic fever outbreak.
BMC Med. Res. Methodol. 2021 May 6

Royer G. et al.
Phylogroup stability contrasts with high within sequence type complex dynamics of Escherichia coli bloodstream infection isolates over a 12-year period.
Genome Med. 2021 May 5

Couffignal C. et al.
Impact of study design and statistical model in pharmacogenetic studies with gene-treatment interaction.
CPT Pharmacometrics Syst. Pharmacol. 2021 May 5

d’Humières C. et al.
Two original observations concerning bacterial infections in COVID-19 patients hospitalized in intensive care units during the first wave of the epidemic in France.
PLoS One 2021 Apr 29

Zeller V. et al.
Influence of the clindamycin-administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study.
Clin. Microbiol. Infect. 2021 Apr 25

Hobson C.A. et al.
Cross resistance to cefiderocol and ceftazidime-avibactam in KPC beta-lactamase mutants and inoculum effect.
Clin. Microbiol. Infect. 2021 Apr 25

Lebourgeois S. et al.
Performance Evaluation of the QIAstat-Dx® Respiratory SARS-CoV-2 Panel.
Int. J. Infect. Dis. 2021 Apr 23

Ghazali DA. et al.
Analysis of the Feasibility of a Vaccination Campaign against Influenza Epidemic and COVID-19 Pandemic in French Emergency Departments: A National Survey.
Vaccines (Basel) 2021 Apr 19

Ben M’Barek I. et al.
Contribution of vaginal culture to predict early onset neonatal infection in preterm prelabor rupture of membranes.
Eur. J. Obstet. Gynecol. Reprod. Biol. 2021 Apr 16

Betton M. et al.
Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19.
Clin. Infect. Dis. 2021 Apr 14

Bizot E. et al.
Shiga toxin-producing Escherichia coli carriage in 959 healthy French infants.
Arch. Dis. Child. 2021 Apr 8

Vauloup-Fellous C. et al.
Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients.
Eur. J. Clin. Microbiol. Infect. Dis. 2021 Mar 29

Gonçalves A. et al.
SARS-CoV-2 viral dynamics in non-human primates.
PLoS Comput. Biol. 2021 Mar 17

Maataoui N. et al.
Impact of rapid multiplex PCR on management of antibiotic therapy in COVID-19-positive patients hospitalized in intensive care unit.
Eur. J. Clin. Microbiol. Infect. Dis. 2021 Mar 17

Gaymard A. et al.
Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021.
Euro Surveill. 2021 Mar 4

Lescure F.X. et al.
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Respir. Med. 2021 Mar 4

Buatois S. et al.
cLRT-Mod: An efficient methodology for pharmacometric model-based analysis of longitudinal phase II dose finding studies under model uncertainty.
Stat. Med. 2021 Mar 2

Czuppon P. et al.
Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action.
PLoS Comput. Biol. 2021 Mar 1

Néant N. et al.
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort.
Proc. Natl. Acad. Sci. USA 2021 Feb 23

Chawki S. et al.
Temocillin as an alternative treatment for acute bacterial cholangitis: a retrospective microbiology susceptibility-based study of 140 episodes.
Eur. J. Clin. Microbiol. Infect. Dis. 2021 Feb 20

Pascucci M. et al.
AI-based mobile application to fight antibiotic resistance.
Nat. Commun. 2021 Feb 19

Saliba R. et al.
Risk Factors for the Environmental Spread of Different Multi-Drug-Resistant-Organisms (MDRO): A Prospective Cohort Study.
J. Hosp. Infect. 2021 Feb 10

Tarhini H. et al.
Long term SARS-CoV-2 infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection.
J. Infect. Dis. 2021 Feb 8

Tubiana S. et al.
High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers – The CoV-CONTACT cohort.
J. Infect. 2021 Feb 3

Flament H. et al.
Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity.
Nat. Immunol. 2021 Feb 2

Contejean A. et al.
Comparing Dynamics and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 Transmissions Among Healthcare Workers of Adult and Pediatric Settings in Central Paris.
Clin. Infect. Dis. 2021 Jan 27

Buetti N. et al.
COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network.
Intensive Care Med. 2021 Jan 27

Rousset F. et al.
The impact of genetic diversity on gene essentiality within the Escherichia coli species.
Nat. Microbiol. 2021 Jan 18

Dupuis C. et al.
Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs.
Crit. Care 2021 Jan 10

Lingas G. et al.
Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin.
PLoS Comput Biol. 2021 Jan 7

Bridier-Nahmias A. et al.
Escherichia coli Genomic Diversity within Extraintestinal Acute Infections Argues for Adaptive Evolution at Play.
mSphere 2021 Jan 6